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Abstract We examined the incidence of ﬁrst primary
central nervous system tumors (PCNST) in California from
2001–2005. This study period represents the ﬁrst ﬁve years
of data collection of benign PCNST by the California
Cancer Registry. California’s age-adjusted incidence rates
(AAIR) for malignant and benign PCNST (5.5 and 8.5 per
100,000, respectively). Malignant PCNST were highest
among non-Hispanic white males (7.8 per 100,000).
Benign PCNST were highest among African American
females (10.5 per 100,000). Hispanics, those with the
lowest socioeconomic status, and those who lived in rural
California were found to be signiﬁcantly younger at diag-
nosis. Glioblastoma was the most frequent malignant
histology, while meningioma had the highest incidence
among benign histologies (2.6 and 4.5 per 100,000,
respectively). This study is the ﬁrst in the US to compare
malignant to benign PCNST using a population-based data
source. It illustrates the importance of PCNST surveillance
in California and in diverse communities.
Keywords Brain and other central nervous system
neoplasms   Epidemiology   Cancer incidence   Ethnic
groups   Health disparities
Introduction
Central nervous system (CNS) cancers are neoplasms of
the neuroepithelial tissue and membranous coverings of the
brain and spinal cord, tumors of the pituitary gland, and
cancers arising from the cranial nerves and CNS hemato-
poietic cells. Compared to other forms of cancer, PCNST
are rare. In California, these cancers generally represent
only 1.5% of incident cancer cases and 2.6% of cancer
deaths [1]. Despite these statistics, PCNST are an impor-
tant source of cancer morbidity and mortality and generate
intense interest from clinicians, researchers, the public
health community, and the general public.
Many population-based epidemiologic studies of
PCNST are methodologically inconsistent and potentially
unreliable. CNS cancers are a heterogeneous group of
diseases, comprising many histopathological forms and
encompassing numerous gross anatomic sites. Their his-
topathological progression may be benign, malignant, or of
uncertain tumor behavior. Although CNS tumor classiﬁ-
cation was standardized by the World Health Organization
(WHO) in 1993, there remains variation in the organization
of histologic codes for presentation and in the creation of
histology sub-groups [2]. Coding trends by neuropatholo-
gists change with time, resulting in erroneous incidence
ﬂuctuations [3]. Furthermore, many epidemiologic studies
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With the enactment of federal Public Law 107-260 in
2004, the Benign Brain Tumor Cancer Registries Amend-
ment Act, all state and metropolitan cancer registries are
required to collect data on benign PCNST and those of
uncertain tumor behavior [4]. Prior to 2004, many state and
metropolitan cancer registries voluntarily collected these
data, including the California Cancer Registry (CCR),
which has been collecting data on benign and uncertain
tumor behavior CNS tumors since 2001. In this study, we
examined the incidence of ﬁrst primary PCNST collected
by the CCR from 2001–2005. For benign PCNST, this
study period represents the ﬁrst ﬁve years of data collection
in California and the ﬁrst population-based study of benign
PCNST in the country. With a population of 36.5 million,
California contains over 12% of the U.S. population, with
broad ethnic, cultural, and socioeconomic representation
[5]. Delineating the epidemiology of PCNST in California
will create a backdrop for future basic, translational, clin-
ical, and public health research and can be used as a
baseline for monitoring incidence trends over time.
Materials and methods
Case identiﬁcation
Cases used in these analyses were identiﬁed using the
California Cancer Registry (CCR), a population-based
registry composed of eight regional registries collecting
cancer incidence and mortality data for the entire popula-
tion of California. In 1985, California state law mandated
the reporting of all newly diagnosed cancers in California,
and statewide implementation began January 1, 1988. This
state law was amended to require the collection of benign
and uncertain behavior brain and other nervous system
tumors beginning January 1, 2001. Cases are reported to
the Chronic Disease Surveillance and Research Branch of
the California Department of Public Health from all hos-
pitals and any other facilities providing care or therapy to
cancer patients residing in California (approximately 2,500
facilities) [6]. Cases diagnosed outside of California, at
autopsy, or from death certiﬁcates were excluded.
For this study, ﬁrst primary cases of malignant, benign
and uncertain tumor behavior brain and other nervous
system tumors diagnosed between January 1, 2001 and
December 31, 2005 and reported to the CCR as of October
2007 were used [7]. Only cases diagnosed or treated at the
reporting facility were included in these analyses. Diag-
noses of 98% of the 24,944 cases were conﬁrmed by
histology (79.0%) and radiography (19.3%); the remaining
1.7% was conﬁrmed by a variety of methods, including but
not limited to cytology and clinical determination. Less
than 0.5% of cases included in these analyses were con-
ﬁrmed by an unknown method. In this manuscript, the term
‘‘uncertain behavior’’ is used and synonymous with ‘‘bor-
derline behavior’’. These terms are deﬁned similarly but
their use is speciﬁc to certain classiﬁcation systems.
Uncertain behavior is used in the International Classiﬁca-
tion of Diseases (ICD) systems [7], while borderline
behavior is the term used by the Centers for Disease
Control and Prevention’s (CDC), National Programs for
Central Cancer Registries (NPCR) [8], Surveillance, Epi-
demiology and End Results (SEER) [9] program of the
National Cancer Institute, and thus the CCR. Additionally,
primitive neuroectodermal tumors are abbreviated
throughout the text and tables as PNET.
Only cases with anatomical sites, histology codes and
tumor behavior deﬁned as reportable in Cancer Reporting
in California: Abstracting and Coding Procedures for
Hospitals, Volume 1, Section II.1.9.1 and Appendix V
were included in these analyses. Anatomical sites included
were the meninges (C70.0–C70.9); brain (C71.0–C71.9);
cerebrum (C71.0); brain lobes (C71.1–C71.4); ventricle,
NOS (C71.5); cerebellum, NOS (C71.6); brain stem
(C71.7); spinal cord (C72.0); cauda equina (C72.1); cranial
nerves (C72.2); pituitary gland (C75.1); craniopharyngeal
duct (C75.2); and pineal gland (C75.3) [10]. For other
selected analyses, overlapping lesions of brain (C71.8);
brain, NOS (C71.9); and/or nervous system, NOS (C72.9)
were included. Although the use of some anatomical sites
and histology codes differed, the 2007–2008 report of the
Central Brain Tumor Registry of the United States
(CBTRUS), 2000–2004, was used as a guide for the
organization of histology codes in Table 2 [11]. In this
study, pilocytic astrocytoma (ICD-O-3, 9421) is classiﬁed
as having benign tumor behavior as is directed in ICD-O-3
[7]. This is contrary to the classiﬁcation stipulated in
Cancer Reporting in California: Abstracting and Coding
Procedures for Hospitals, Volume 1, Section II.1.9.1 and
Appendix V, in which it is classiﬁed as malignant, in
accordance with SEER reporting requirements [10].
The collection of benign and borderline brain and other
nervous system tumors became a statewide effort beginning
in 2001; however, the nationwide effort did not begin until
2004. Inconsistencies in data collection may have occurred
as a result of coding rule changes for cases diagnosed in
2004 and 2005. To utilize all eligible cases, we identiﬁed
inconsistencies by cross tabulations of cases by histology,
tumor behavior, and anatomical site; these were reviewed
by the authors, a regional registry quality control coordi-
nator, and a neurosurgeon to determine the accuracy of
coding and the appropriate categorization for presentation.
Based on their assessment, approximately 400 cases were
reassigned histology, tumor behavior, and/or anatomical
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123site codes, and approximately 100 cases were deleted from
the research database entirely for this study. Speciﬁcally, all
craniopharyngiomas were recoded to uncertain behavior of
the craniopharyngeal duct. All cases coded as benign ade-
nomas (ICD-O-3 8140) of the pituitary gland were recoded
to pituitary adenomas (ICD-O-3 8272). Some cases
(n = 65), were recoded based on visual review of the
individual case abstract for various reasons. Cases with
ICD-O-3 codes 9450, 9391-9393, 9380, 9370-9372, were
recoded to malignant behavior. Myxopapillary ependymo-
mas were recoded to uncertain behavior. The cases coded
as hemangioblastic meningioma were recoded to heman-
gioblastoma.
Variables
The age, sex, race/ethnicity, and residential address of the
patients that were used in these analyses were collected by
the CCR from each patient’s medical record. Race/eth-
nicity was derived from patient self-identiﬁcation,
assumptions based on personal appearance, or inferences
based on the race/ethnicity of the parents, birthplace, sur-
name, or maiden name. Race/ethnicity was classiﬁed into
four mutually exclusive categories of non-Hispanic white,
non-Hispanic black, Hispanic, and Asian/Paciﬁc Islander.
Hispanic ethnicity identiﬁcation was enhanced by the use
of computerized comparisons to the 1980 U.S. census list
of Hispanic surnames. Patients identiﬁed as Hispanic on
the medical record, or patients identiﬁed as white, black, or
of unknown race with a Hispanic surname were classiﬁed
as Hispanic. Use of this method can misclassify some
persons as Hispanic when they are not [12].
Residential census tracts of cases, including those who
used post ofﬁce boxes as residential addresses and the
denominator population were classiﬁed by the 2000 Rural
Urban Commuting Areas (RUCA) codes. The RUCAs
were developed by the University of Washington’s Rural
Health Research Center and the Economic Research Ser-
vice [13]. The RUCAs are a census tract-based taxonomy
that utilizes the standard Census Bureau Urbanized Area
and Urban Cluster deﬁnitions in combination with other
work that commuted data to characterize the nation’s
census tracts regarding their urban and rural status and
functional relationships [14]. For these analyses, urban and
rural census tracks in California were dichotomized based
on Categorization C as recommended in ‘‘Using RUCA
Data,’’ published by the Rural Health Research Center
[14].
Socioeconomic status (SES) was assigned based on the
patient’s census block group (2000 U.S. census) derived
from their address at time of initial diagnosis as reported in
the medical record. This SES variable is an index that
utilizes education, employment characteristics, median
household income, proportion of the population living
200% below the Federal Poverty Level, median rent, and
median housing value of census tract of residence for case
and denominator population. A principal components
analysis was used to identify quintiles of SES ranging from
one, the lowest, to ﬁve, the highest [15].
Statistical analysis
Counts and proportions were calculated using SAS 9.0
(SAS Institute, Cary, NC). Age-adjusted incidence rates
(AAIR) were adjusted by the direct method and standard-
ized to the 2000 U.S. population [16]. Age-speciﬁc
incidence rates (ASIR) were calculated speciﬁc to each
5 year age group. Denominators were based on the 2000
U.S. census. All rates were calculated using SEER*Stat
6.3.6 (National Cancer Institute, Silver Spring, MD). Sta-
tistical comparisons of incidence rates were assessed using
their respective conﬁdence intervals [16]. If two compar-
ative AAIR or ASIR conﬁdence intervals do not overlap,
the difference in the rates is considered statistically
signiﬁcantly.
Results
We identiﬁed 24,923 cases of ﬁrst PCNST in the CCR from
2001 to 2005. A total of 9,236 (37.1%) cases were malig-
nant, 14,057 (56.4%) cases were benign, and 1,630 (6.5%)
cases were of uncertain tumor behavior. As shown in
Table 1,ourstudypopulationwas 59.5%adult,20–64 years
old; 54.5% female; 60.8% non-Hispanic white; 46.5% of
high SES; and 93.5% urban residents at time of diagnosis.
The proportion of cases by age groups, SES, and location of
residence at diagnosis was similar across tumor behavior,
although tumors of uncertain tumor behavior appeared to
occur more in the 0–19 year old age group than malignant
and benign. There were statistically signiﬁcant differences
in the median age at diagnosis of patients with PCNST by
tumor behavior (P\0.05). For malignant PCNST, males,
ethnic minorities, those of low SES, and those who lived in
urban areas were signiﬁcantly younger at diagnosis than
females, those of high SES, non-Hispanic whites, and those
who lived in rural areas. For benign PCNST, Hispanics and
Asian/Paciﬁc Islanders, those of low SES, and those who
lived in urban areas were signiﬁcantly younger at diagnosis
(P\0.05). The proportional incidence of PCNST, regard-
less of tumor behavior, was highest among those at the
highest SES.
The overall sex-speciﬁc AAIR for malignant PCNST
was highest among males, at 6.6 per 100,000 (C.I., 6.4, 6.8).
For benign PCNST, the AAIR was highest for females, at
10.0 per 100,000 (C.I., 9.8, 10.2). The sex-speciﬁc AAIR
J Neurooncol (2009) 94:249–261 251
123for PCNST of uncertain tumor behavior were nearly equal
for males and females at 1.0 and 0.9 per 100,000.
Age-speciﬁc incidence of malignant tumors was lowest,
for both males and females, in their early 20s. The ASIR
for males was higher than the ASIR for females, with the
gap increasing between ages 40 and 79. Incidence of
malignant tumors peaked for both males and females in
their late 70s and decreased thereafter. In contrast to
malignant tumors, benign tumors were lowest in childhood
and adolescence and increased with increasing age. ASIRs
for benign tumors were consistently higher among females
for all age groups except ages 10–14 (Fig. 1).
In Fig. 2, incidence of malignant tumors was highest for
non-Hispanic white males, followed by Hispanic males
(7.8 and 5.7 per 100,000, respectively), and lowest for
Asian/Paciﬁc Islander and non-Hispanic black females (3.0
and 3.1 per 100,000, respectively). Incidence of benign
tumors was highest for all females, with rates for non-
Hispanic black, non-Hispanic white, and Hispanic females
being very close (10.5, 10.2 and 9.8 per 100,000,
respectively).
In Table 2 we see that malignant PCNST were primarily
glioblastoma (45.3%), followed distantly by lymphoma
(7.5%) and anaplastic astrocytoma (7.0%). The vast
majority of benign tumors consisted of meningiomas
(51.6%), pituitary tumors (24.1%), and nerve sheath tumors
(18.0%). Tumors of uncertain behavior were distributed
similarly to benign tumors, with the largest proportion
being meningiomas (26.0%), followed by craniopharyn-
giomas (16.6%), which are tumors of the sellar region like
those of the pituitary gland. These two groups were
followed by hemangioblastoma (13.3%), which are con-
sidered tumors of the meninges.
As shown in Table 3, the highest incident histologies
were glioblastoma (2.6 per 100,000) for malignant and
meningioma (4.5 per 100,000) for benign PCNST. The
AAIR for glioblastomas was 1.7 times greater in males
compared to females, while the rate of meningiomas was
2.3 times greater in females compared to males. Non-
Hispanic white males had the highest AAIR of glioblas-
toma (3.9 per 100,000), which was signiﬁcantly higher
than all other race/ethnic groups by sex. Non-Hispanic
Table 1 Number of cases and percent of ﬁrst primary central nervous system tumors, population demographic characteristics and median age at
diagnosis by behavior, California, 2001–2005
Demographic characteristics Malignant Benign Uncertain Total
n % Median age n % Median age n % Median age n %
Age group, years
0–19 1,114 12.1 698 5.0 284 17.4 2,096 8.4
20–64 5,202 56.3 8,676 61.7 941 57.7 14,819 59.5
65? 2,920 31.6 4,683 33.3 405 24.8 8,008 32.1
Sex
Male 5,232 56.6 53* 5,277 37.5 55 830 50.9 44* 11,339 45.5
Female 4,004 43.4 57 8,780 62.5 56 800 49.1 50 13,584 54.5
Race/ethnicity
Non-Hispanic White 5,965 64.6 58 8,266 58.8 58 919 56.4 53 15,150 60.8
Non-Hispanic Black 378 4.1 51* 902 6.4 57 116 7.1 47* 1,396 5.6
Hispanic 2,122 23.0 43* 3,092 22.0 47* 424 26.0 34* 5,638 22.6
Asian-Paciﬁc Islander 726 7.9 51* 1,605 11.4 57* 157 9.6 48* 2,488 10.0
Other/unknown 45 0.5 40* 192 1.4 52* 14 0.9 49 251 1.0
Socioeconomic status
Low 3,020 32.7 51* 4,573 32.5 54* 585 35.9 42* 8,180 32.8
Medium 1,907 20.6 56 2,909 20.7 56 352 21.6 50 5,169 20.7
High 4,309 46.7 56 6,575 46.8 56 693 42.5 49 11,579 46.5
Level of urbanization
Rural 631 6.8 58 859 6.1 58 127 7.8 54 1,617 6.5
Urban 8,605 93.2 54* 13,198 93.9 55* 1,503 92.2 47 23,306 93.5
Total 9,236 14,057 1,630 24,923
* P-value\0.05; female; Non-Hispanic white; SES high and rural were used as the referent catagories
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123white males had signiﬁcantly higher AAIRs than other
race/ethnic groups; a higher incidence of anaplastic
astrocytoma, except for Hispanic males; and a higher
incidence of nerve sheath tumors, except for Asian/Paciﬁc
Islander males. The AAIRs for astrocytoma, NOS, and
pilocytic astrocytoma were signiﬁcantly higher for non-
Hispanic white males compared to Asian/Paciﬁc Islander
males. Among females, non-Hispanic white females had
the highest rate of glioblastoma (2.4 per 100,000),
regardless of race/ethnicity. Non-Hispanic white females
had a signiﬁcantly higher AAIR compared to other race/
ethnic groups for nerve sheath tumors, except for Asian/
Paciﬁc Islander females.
Non-Hispanic black males had signiﬁcantly higher
AAIR for pituitary tumors (3.8 per 100,000) compared to
all other race/ethnic groups by sex and a signiﬁcantly
higher AAIR for meningiomas compared to Hispanic
males. Non-Hispanic black females had a signiﬁcantly
higher AAIR for pituitary tumors compared to males and
females in other race/ethnic groups, except non-Hispanic
black males and Hispanic males and females.
Table 4showsthatmalignanttumorsoccurredmostoften
among adults, 20–64 years old. The exception was PNET/
medulloblastoma (71.9%) which occurred mostly among
children, adolescents and teens, 0–19 years old. Adults aged
65 years and older had higher proportions of glioblastomas
(44.3%) and lymphomas (40.6%). Malignant tumors
occurred chieﬂy among males with the exception of glioma
and pilocytic astrocytoma, which occurred slightly more
often among females. Hispanics had higher proportions
of PNET/medulloblastoma (47.4%) and ependymoma/
anaplastic ependymoma (33.5%). A higher proportion of
lymphoma (13.5%) was seen among Asian/Paciﬁc Islanders
compared to other histologies. Most cases lived in areas of
high SES, except for PNET/medulloblastoma, where 41.9%
of the cases were of the lowest SES group.
Patients with benign tumors were more similar demo-
graphically across histology groups than those with
malignant tumors. Unlike malignant tumors, benign tumors
occurred chieﬂy among females (62.5%). Benign PCNST
occurred most often among adults, 20–64 years old
(61.7%); non-Hispanic whites (58.8%) followed by His-
panics (22.0%); those in the higher SES groups (46.8%)
followed by those in the lowest (32.5%); and urban resi-
dents (93.9%) at time of diagnosis. Meningiomas were
highest among females (73.5%). Pilocytic astrocytoma
(76.0%) occurred mostly among children, adolescents and
teens, 0–19 years old. Among Hispanics and non-Hispanic
blacks, tumors of the pituitary gland occurred more often
than other anatomic sites (33% and 9.5%, respectively).
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123Discussion
Thirty-seven percent of California’s PCNST were found to
be malignant and 56% benign. The AAIR of malignant
PCNST in California was 5.8 cases per 100,000 persons,
and benign PCNST was 8.5 cases per 100,000 persons.
Consistent with ﬁndings of other studies, the incidence
of malignant tumors increased with increasing age except
for the youngest (0–14 years) and oldest ([65 years)
members of our study population [11, 17, 18]. A similar,
but more monotonic age-related pattern was found for
benign tumors. The highest incidence for both malignant
and benign PCNST was among adults, 20–64 years old.
Median age at diagnosis ranged widely by sex, race/eth-
nicity, SES, and the level of urbanization of patient
residence. Signiﬁcant differences were found in median
age at diagnosis by sex for malignant but not for benign
PCNST. Non-Hispanic whites were the oldest (57 years
old) while Hispanics were the youngest (41 years old).
Those in the lowest SES level and those who lived in rural
California were signiﬁcantly younger at the time of diag-
nosis. Disparities in median age at diagnosis could indicate
etiologic differences in PCNST or disparities in healthcare
utilization, access and diagnostics among these groups.
The incidence of malignant PCNST was highest among
non-Hispanic white males, followed by Hispanic males
[17, 19, 20]. Benign PCNST in California occurred more
often among females. The AAIRs were similar across all
race/ethnic groups, lead slightly by non-Hispanic black
females (10.5 per 100,000). In our race/ethnicity analyses,
we found signiﬁcantly higher AAIRs for glioblastoma,
pilocytic astrocytoma, anaplastic astrocytoma, oligoden-
droglioma, and nerve sheath tumors among non-Hispanic
white males and females. In comparison, non-Hispanic
black males and females had signiﬁcantly higher rates of
meningiomas and pituitary tumors [21–28]. We found
higher incidence rates of nerve sheath tumors among
Asian/Paciﬁc Islanders. Unlike other studies, we found that
the AAIR of pituitary tumors among Asian/Paciﬁc
Islanders was nearly the same rate as reported for non-
Hispanic whites [29–32].
Overall PCNST proportional incidence, regardless of
tumor behavior, was highest for the highest SES group,
followed by the lowest SES group [28, 33]. Inskip et al.
(2003) found similar results for gliomas and meningiomas,
in which the incidence was highest among those with more
education, greater income, and private insurance. The
incidence among those with public insurance was also
somewhat higher, possibly betraying a reporting bias
linked to population healthcare coverage [33, 34]. Differ-
ential tumor detection and reporting between those with
and without health insurance may account for some of the
observed differences.
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123Table 3 Age-Adjusted Incidence Rates (AAIR)* of selected ﬁrst primary malignant and benign central nervous system tumors by histology and
sex, California, 2001–2005
Behavior Histology Sex Total NH White NH Black Hispanic API
AAIR 95% CI AAIR 95% CI AAIR 95% CI AAIR 95% CI AAIR 95% CI
Malignant Astrocytoma,
anaplastic
Total 0.4 0.3, 0.4 0.5 0.4, 0.5 0.1 0.1, 0.2 0.3 0.3, 0.4 0.2 0.2, 0.3
Male 0.4 0.4, 0.5 0.6 0.5, 0.6 0.1 0.0, 0.2 0.4 0.3, 0.5 0.3 0.2, 0.4
Female 0.3 0.3, 0.4 0.4 0.3, 0.5 0.2 0.1, 0.3 0.3 0.2, 0.4 0.2 0.1, 0.3
Astrocytoma, NOS Total 0.3 0.3, 0.4 0.4 0.4, 0.5 0.2 0.2, 0.4 0.3 0.3, 0.4 0.2 0.1, 0.2
Male 0.4 0.3, 0.4 0.5 0.4, 0.5 0.4 0.2, 0.6 0.4 0.3, 0.5 0.2 0.1, 0.3
Female 0.3 0.3, 0.3 0.3 0.3, 0.4 0.1 0.1, 0.3 0.3 0.2, 0.4 0.2 0.1, 0.3
Glioblastoma Total 2.6 2.5, 2.7 3.1 3.0, 3.2 1.5 1.3, 1.8 2.3 2.1, 2.5 1.2 1.1, 1.4
Male 3.3 3.1, 3.4 3.9 3.7, 4.1 2.0 1.6, 2.5 2.8 2.5, 3.1 1.6 1.3, 1.9
Female 2.0 1.9, 2.1 2.4 2.3, 2.5 1.1 0.9, 1.5 1.9 1.7, 2.2 0.9 0.7, 1.1
Oligodendroglioma Total 0.3 0.2, 0.3 0.3 0.3, 0.4 0.1 0.0, 0.2 0.2 0.2, 0.2 0.2 0.1, 0.2
Male 0.3 0.3, 0.3 0.4 0.3, 0.5 0.1 0.0, 0.3 0.2 0.1, 0.3 0.2 0.1, 0.3
Female 0.2 0.2, 0.2 0.3 0.2, 0.3 0.1 0.0, 0.2 0.2 0.1, 0.3 0.1 0.1, 0.2
Anaplastic
oligodendroglioma
Total 0.1 0.1, 0.1 0.2 0.1, 0.2 0.0 0.0, 0.1 0.1 0.1, 0.1 0.1 0.1, 0.1
Male 0.1 0.1, 0.1 0.1 0.1, 0.2 0.1 0.0, 0.2 0.1 0.1, 0.2 0.1 0.1, 0.2
Female 0.1 0.1, 0.1 0.2 0.1, 0.2 0.0 0.0, 0.1 0.1 0.0, 0.1 0.1 0.0, 0.1
Ependymomas,
anaplastic
Total 0.2 0.2, 0.3 0.3 0.2, 0.3 0.2 0.1, 0.3 0.2 0.2, 0.3 0.2 0.1, 0.2
Male 0.2 0.2, 0.3 0.3 0.2, 0.3 0.2 0.1, 0.4 0.2 0.2, 0.3 0.1 0.1, 0.2
Female 0.2 0.2, 0.3 0.3 0.2, 0.3 0.2 0.1, 0.3 0.2 0.2, 0.3 0.2 0.1, 0.3
Mixed glioma Total 0.2 0.2, 0.2 0.2 0.2, 0.3 0.1 0.0, 0.2 0.1 0.1, 0.2 0.2 0.1, 0.2
Male 0.2 0.2, 0.2 0.3 0.2, 0.3 0.1 0.0, 0.2 0.1 0.1, 0.2 0.2 0.1, 0.3
Female 0.2 0.1, 0.2 0.2 0.1, 0.2 0.1 0.0, 0.3 0.1 0.1, 0.2 0.2 0.1, 0.2
Glioma malignant, NOS Total 0.3 0.3, 0.3 0.3 0.3, 0.4 0.3 0.2, 0.4 0.3 0.2, 0.3 0.2 0.2, 0.3
Male 0.3 0.3, 0.4 0.4 0.3, 0.4 0.3 0.1, 0.5 0.3 0.2, 0.4 0.3 0.2, 0.4
Female 0.3 0.2, 0.3 0.3 0.2, 0.4 0.3 0.2, 0.5 0.3 0.2, 0.4 0.2 0.1, 0.3
PNET/Meduloblastoma Total 0.2 0.2, 0.2 0.2 0.2, 0.3 0.1 0.1, 0.2 0.2 0.2, 0.3 0.2 0.1, 0.2
Male 0.3 0.2, 0.3 0.3 0.2, 0.4 0.1 0.0, 0.2 0.3 0.2, 0.4 0.1 0.1, 0.2
Female 0.2 0.1, 0.2 0.2 0.1, 0.2 0.1 0.0, 0.2 0.2 0.1, 0.2 0.2 0.1, 0.3
Lymphomas Total 0.4 0.4, 0.5 0.4 0.4, 0.5 0.4 0.3, 0.5 0.4 0.3, 0.5 0.5 0.4, 0.6
Male 0.5 0.5, 0.6 0.5 0.4, 0.6 0.4 0.3, 0.6 0.5 0.4, 0.6 0.6 0.4, 0.7
Female 0.3 0.3, 0.4 0.3 0.3, 0.4 0.3 0.2, 0.5 0.3 0.2, 0.4 0.4 0.3, 0.5
Benign Pilocytic astrocytoma Total 0.3 0.2, 0.3 0.4 0.3, 0.4 0.2 0.2, 0.3 0.2 0.2, 0.2 0.1 0.1, 0.2
Male 0.3 0.2, 0.3 0.4 0.3, 0.4 0.2 0.1, 0.4 0.2 0.2, 0.3 0.1 0.1, 0.2
Female 0.3 0.2, 0.3 0.4 0.3, 0.5 0.2 0.1, 0.4 0.2 0.2, 0.3 0.2 0.1, 0.3
Nerve sheath Total 1.5 1.4, 1.6 1.8 1.7, 1.8 0.7 0.5, 0.9 1.0 0.9, 1.1 1.5 1.3, 1.7
Male 1.6 1.5, 1.7 1.9 1.7, 2.0 0.8 0.5, 1.0 0.9 0.8, 1.1 1.6 1.4, 1.9
Female 1.4 1.4, 1.5 1.7 1.5, 1.8 0.6 0.4, 0.9 1.0 0.9, 1.2 1.4 1.2, 1.6
Meningioma Total 4.5 4.4, 4.6 4.7 4.5, 4.8 5.0 4.5, 5.5 4.0 3.7, 4.2 4.2 3.9, 4.5
Male 2.7 2.5, 2.8 2.9 2.7, 3.1 3.2 2.6, 3.8 2.0 1.7, 2.2 2.3 2.0, 2.7
Female 6.1 5.9, 6.3 6.3 6.1, 6.5 6.5 5.8, 7.2 5.7 5.3, 6.1 5.8 5.3, 6.2
Pituitary tumors Total 2.0 1.9, 2.1 1.7 1.6, 1.8 3.2 2.9, 3.6 2.5 2.3, 2.7 1.8 1.6, 2.0
Male 2.1 2.0. 2.2 1.8 1.7, 2.0 3.8 3.2, 4.5 2.5 2.3, 2.8 1.8 1.5, 2.1
Female 2.0 1.9, 2.1 1.6 1.5, 1.7 3.0 2.5, 3.5 2.6 2.4, 2.8 1.8 1.6, 2.1
* Age-adjusted incidence rates are per 100,000 population. Rates are standardized to the 2000 US population
PNET primitive neuroectodermal tumors
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123Table 4 Number of cases and percent of selected ﬁrst primary malignant and benign central nervous system tumors by demographics and
histology, California, 2001–2005
Malignant
Demographic characteristics Anaplastic
astrocytoma
Glioblastoma Ependymoma/
anaplastic
ependymoma
Glioma,
NOS
PNET/
medullo-
blastoma
Lymphoma Other Total
n % n % n % n % n % n % n % n %
Age group (years)
0–19 52 8.1 53 1.3 128 30.6 166 33.4 287 71.9 18 2.6 410 17.1 1,114 12.1
20–64 443 68.8 2,277 54.5 253 60.5 183 36.8 110 27.6 394 56.8 1,542 64.1 5,202 56.3
65? 149 23.1 1,850 44.3 37 8.9 148 29.8 \5 0.5 282 40.6 452 18.8 2,920 31.6
Sex
Male 363 56.4 2,441 58.4 212 50.7 247 49.7 248 62.2 398 57.3 1,323 55.0 5,232 56.6
Female 281 43.6 1,739 41.6 206 49.3 250 50.3 151 37.8 296 42.7 1,081 45.0 4,004 43.4
Race/ethnicity
Non-Hispanic White 423 65.7 3,059 73.2 219 52.4 276 55.5 164 41.1 400 57.6 1,424 59.2 5,965 64.6
Non-Hispanic Black 16 2.5 143 3.4 23 5.5 29 5.8 13 3.3 38 5.5 116 4.8 378 4.1
Hispanic 152 23.6 724 17.3 140 33.5 140 28.2 189 47.4 156 22.5 621 25.8 2,122 23.0
Asian-Paciﬁc Islander 50 7.8 242 5.8 34 8.1 47 9.5 31 7.8 94 13.5 228 9.5 726 7.9
Other/unknown \5 0.5 12 0.3 \5 0.5 5 1.0 \5 0.5 6 0.9 15 0.6 45 0.5
Socioeconomic status
Low 218 33.9 1,218 29.1 157 37.6 184 37.0 167 41.9 245 35.3 831 34.6 3,020 32.7
Medium 131 20.3 875 20.9 69 16.5 105 21.1 77 19.3 141 20.3 509 21.2 1,907 20.6
High 295 45.8 2,087 49.9 192 45.9 208 41.9 155 38.8 308 44.4 1,064 44.3 4,309 46.7
Level of urbanization
Rural 52 8.1 305 7.3 26 6.2 34 6.8 19 4.8 47 6.8 148 6.2 631 6.8
Urban 592 91.9 3,875 92.7 392 93.8 463 93.2 380 95.2 647 93.2 2,256 93.8 8,605 93.2
Total 644 4,180 418 497 399 694 2,404 9,236
Benign
Pilocytic astrocytoma Nerve sheath tumors Meningioma Pituitary tumors Other Total
n % n % n % n % n % n %
Age group (years)
0–19 371 76.0 48 1.9 30 0.4 143 4.2 106 27.1 698 5.0
20–64 111 22.7 2,037 80.3 3,863 53.2 2,444 72.2 221 56.5 8,676 61.7
65? 6 1.2 452 17.8 3,364 46.4 797 23.6 64 16.4 4,683 33.3
Sex
Male 240 49.2 1,290 50.8 1,923 26.5 1,634 48.3 190 48.6 5,277 37.5
Female 248 50.8 1,247 49.2 5,334 73.5 1,750 51.7 201 51.4 8,780 62.5
Race/ethnicity
Non-Hispanic White 250 51.2 1,639 64.6 4,626 63.7 1,528 45.2 223 57.0 8,266 58.8
Non-Hispanic Black 31 6.4 74 2.9 460 6.3 322 9.5 15 3.8 902 6.4
Hispanic 168 34.4 423 16.7 1,273 17.5 1,116 33.0 112 28.6 3,092 22.0
Asian-Paciﬁc Islander 30 6.1 326 12.8 829 11.4 385 11.4 35 9.0 1,605 11.4
Other/unknown 9 1.8 75 3.0 69 1.0 33 1.0 6 1.5 192 1.4
Socioeconomic status
Low 191 39.1 630 24.8 2,323 32.0 1,299 38.4 130 33.2 4,573 32.5
Medium 94 19.3 488 19.2 1,537 21.2 689 20.4 101 25.8 2,909 20.7
High 203 41.6 1,419 55.9 3,397 46.8 1,396 41.3 160 40.9 6,575 46.8
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123As in other studies, glioblastoma was the dominant
histologic category for malignant PCNST (43%) in Cali-
fornia [35, 36]. Although the proportion of cases we found
in California was exceedingly higher than that found by
others [11, 37], California’s AAIR (2.6 per 100,000 cases)
was lower than those recorded elsewhere, which range
from 3.1 to 4.8/100,000 [11, 38, 39]. The AAIR of lym-
phoma (0.4 per 100,000) was similar in California to that
reported elsewhere [11, 38–40], despite changes in their
histological classiﬁcation and their effect over time [41].
The dominant histologic categories for benign PCNST
were meningiomas (53.5%), tumors of the pituitary gland
(24.9%), and tumors of the nerve sheath (18.7%), collec-
tively representing 97% of California’s benign tumor cases.
The AAIRs for meningiomas, tumors of the pituitary gland,
and tumors of the nerve sheath were 4.5, 2.0, and 1.5 per
100,000, respectively. Californian rates for meningiomas
were similar to those reported by some other studies [11,
35, 38, 39, 42] but not all [43]. The rate of pituitary tumors
in California was higher than that reported by CBTRUS,
1.37 per 100,000 [11], while the incidence rate for tumors
of the nerve sheath was the same as that reported for the
nation.
Cancer incidence is difﬁcult to compare across geo-
graphical areas, time-periods and information sources.
Data used in national and international incidence studies
can differ in diagnostic and neuropathological assessment,
case ascertainment practices [44–47]. Some studies are
single institution or if population-based may lack a sufﬁ-
cient case population to calculate incidence rates or if rates
can be calculated, the use of the world standard population
for incidence rates standardization rather than the U.S.
standard population [48, 49].
Among U.S. CNS tumor incidence studies, counts and
rates can vary by data collection sources and tumor clas-
siﬁcations systems. All national CNS tumor incidence
statistics derived cases from one of four centralized data
collection sources: the NPCR from the CDC; the North
American Association of Central Cancer Registries (NA-
ACCR); SEER and CBTRUS. Both NPCR and NAACCR
are population-based and cover more than 95% of the U.S.
population [8, 50], while SEER, a non-random sample of
central cancer registries, represents 26% of the population
[9]. CBTRUS differs from these agencies since it is a
voluntary repository for CNS tumor data. In 1999,
CBTRUS was estimated to cover 15% of the U.S. popu-
lation with contributions from 16 state registries (excluding
California) [11, 51]. All of these cancer data collection
agencies use the ICD-O tumor classiﬁcation system [7];
whereas neuropathologists use the WHO grading system,
which is speciﬁc to classifying CNS tumors [52]. Both of
these tumor malignancy scales were created by the World
Health Organization and can differ substantially, one
essential difference is in tumor behavior categories. The
ICD-O category of uncertain tumor behavior applies to
CNS tumors, whereas the WHO grading scheme does not
have an option for coding tumors of uncertain behavior.
Coding discrepancies can occur at the individual pathology
report level. This issue is further complicated by the
application of data collection agency speciﬁc coding rules.
Pilocytic astrocytoma is considered benign using the WHO
grading system and ICD-O-3, but it is classiﬁed as malig-
nant for reporting purposes by NAACCR and SEER and
thus all North American central tumor registries. Given that
pilocytic astrocytoma is a high-incidence histology, its
inclusion or exclusion could signiﬁcantly sway pediatric
PCNST statistics. On the other hand, some statistical
sources choose not to partition histologies by tumor
behavior, thus the incidence of CNS tumors calculated by
these sources can appear higher than from other sources
[11].
Other differences in CNS tumor incidence statistics can
arise from the inclusion of all CNS tumors from a single
case, regardless of tumor sequence (ﬁrst primary tumors
versus all primary tumors) and the organization of tumor
histology codes. The CCR as well as all member central
cancer registries of NPCR and NAACCR, use the SEER
program’s incidence site recode system that standardizes
ICD-O histology subgroups [7, 9]. When comparing the
incidence of pituitary gland tumors between sources, we
Table 4 continued
Benign
Pilocytic astrocytoma Nerve sheath tumors Meningioma Pituitary tumors Other Total
n % n % n % n % n % n %
Level of urbanization
Rural 35 7.2 165 6.5 469 6.5 159 4.7 31 7.9 859 6.1
Urban 453 92.8 2,372 93.5 6,788 93.5 3,225 95.3 360 92.1 13,198 93.9
Total 488 2,537 7,257 3,384 391 14,057
NOS not otherwise speciﬁed, PNET primitive neuroectodermal tumors
258 J Neurooncol (2009) 94:249–261
123found wide variation in the ICD-O-3 histology codes used
by CBTRUS and SEER. These code subgroup differences
may explain a nearly two-fold difference in reported inci-
dence in California compared to the nation, as reported by
CBTRUS [11].
This is the ﬁrst study to examine both malignant and
benign PCNST in California. California is a large, heavily
populated state with a diverse ethnic, cultural, and socio-
economic population. This diversity is reﬂected in the CCR,
and we were able to conduct robust analyses and make
comparisons that few others can perform. The CCR’s epi-
demiologic value stems from the 1988 state-mandated
comprehensivereportingofcancercasesfromallphysicians,
hospitals, clinics, treatment facilities and pathology labora-
tories. Because a single standard is used for statewide data
collection, quality assurance, and training and education for
cancer registration, we acquire optimal case ascertainment
and a high level of accuracy for many data items.
Our study and data source are not without limitations.
This study was conducted solely using the CCR and was
not supplemented with other data. The CCR data are col-
lected for the purpose of surveillance and can be less
detailed than those derived from medical records to support
the design of a speciﬁc research study. Population-based
cancer registry data are derived from many sources, thus,
the quality of some variables may vary. Individual-level
social indicators are not available to the CCR. Our SES
measure is a composite of census-derived data and is more
efﬁcient for data analysis, and it avoids biases inherent in
the use of individual component indicators. Another
potential source of error is the misclassiﬁcation of cases.
Despite a rigorous data review and cleaning process, cases
could have been misclassiﬁed based on tumor behavior,
histology, and/or anatomical site.
Cancer surveillance identiﬁes populations at greatest
risk and which of their speciﬁc population attributes are
associated with disease, providing valuable insights into
disease etiology and prevention. This study of California
PCNST establishes a foundation for future studies to
examine age-group differences (i.e., children and seniors),
speciﬁc histologies (i.e., glioblastoma and pituitary
tumors), risk factors, and incidence trends over time.
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